Shuttle Pharmaceuticals Holdings Inc (SHPH) USD0.00001

Sell:$0.30Buy:$0.31$0.01 (4.52%)

Prices delayed by at least 15 minutes
Sell:$0.30
Buy:$0.31
Change:$0.01 (4.52%)
Prices delayed by at least 15 minutes
Sell:$0.30
Buy:$0.31
Change:$0.01 (4.52%)
Prices delayed by at least 15 minutes

Company Information

About this company

Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.

Key people

Anatoly Dritschilo
Chairman of the Board, Chief Scientific Officer
Peter Dritschilo
President, Chief Operating Officer
Christopher R. Cooper
Interim Chief Executive Officer
Timothy J. Lorber
Chief Financial Officer
Tyvin A. Rich
Chief Medical Officer, Chief Clinical Officer
Oleh Nabyt
Director
George Scorsis
Director
Joseph Tung
Director
Steven Richards
Independent Director
Click to see more

Key facts

  • EPIC
    SHPH
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US8256933024
  • Market cap
    $1.89m
  • Employees
    9
  • Shares in issue
    6.26m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.